Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Ganesh Shanmugasundaram Anusuya


Ganesh Shanmugasundaram Anusuya

Sree Balaji Medical College and Hospital, India

Biography

Dr Ganesh .S.A  has been working in the field of HIV/AIDS since 2006 in India .Has worked as Tamil nadu State AIDS Control (TANSACS) STI medical officer , ART medical officer and HIV Community care centre medical officer . After undergraduation , completed his fellowship in HIV Medicine from Government Hospital of Thoracic Medicine (GHTM), Tambaram ,  which is a centre of excellence for HIV treatment , care and support in India. Has been selected as best outgoing fellow and worked as chief fellow in International Training and Education Centre for Health , India. Subsequently completed his MD in Community Medicine from Sree Balaji Medical College and Hospital (SBMCH) , Bharath University,  Chennai. He was the first person as principal investigator  to study about discordant response to ART in patients  enrolled in a Government programme in India. Has done International Presentations of his research work in Africa , UK , India , France , and in USA with many publications .Has been nominated by GHTM and SBMCH for the SAARC Prize on HIV/AIDS 2016  pertaining to his contributions in HIV research . His area of research interest are discordant response to ART , virology , Quality of life , clinical immunology and public health . Currently  involved in HIV research , undergraduate & postgraduate teaching , incharge of free medical camp activities , guiding PhD candidates , conducting conferences , CME , and Public health awareness programmes  in SBMCH as an assistant professor in community medicine department .  

Abstract

Abstract : Immunological and virological discordance in patients on antiretroviral therapy: Still a grey area in HIV research